TC BioPharm (Holdings) plc

TC BioPharm (Holdings) plc (TCBP) priced its initial public offering on Feb 14, 2022 at $4.24 per share, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $82.9M. Benchmark was lead-left underwriter. Golenbock Eiseman Assor Bell & Peskoe and Addleshaw Goddard advised the company and Lucosky Brookman advised the underwriters.

TC BioPharm (Holdings) plc is a Scotland-based clinical-stage biopharmaceutical company developing immunotherapies on its allogeneic gamma delta T cell platform. Its cell therapies are designed to combat cancers and viral infections, with phase II-into-pivotal studies planned.

Status

IPO

Ticker

TCBP

Exchange

Nasdaq Capital Market

Priced

Feb 14, 2022

IPO price

$4.24

Market cap at IPO price

$82.9M

First filed

Oct 26, 2021

Underwriters

Benchmark

Company counsel

Golenbock Eiseman Assor Bell & Peskoe and Addleshaw Goddard

Underwriters' counsel

Lucosky Brookman

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.